期刊文献+

多西紫杉醇联合卡铂与氟尿嘧啶联合卡铂治疗局部晚期鼻咽癌近期疗效的比较 被引量:14

Comparison of the short-term efficacy of two inductive chemotherapy regimens for locally advanced nasopharyngeal carcinoma:docetaxal plus carboplatin versus 5-fluorouracil plus carboplatin
下载PDF
导出
摘要 背景与目的:以铂类为基础联合氟尿嘧啶(5-fluorouracil,5-FU)方案是鼻咽癌患者最常用方案,但患者的疗效一直维持在50%~60%。多西紫杉醇是治疗头颈部恶性肿瘤有效的单药,其给药方式简单、给药时间短。本研究通过比较多西紫杉醇联合卡铂(TC)方案与5-FU联合卡铂(FC)方案对局部晚期鼻咽癌患者的近期疗效和不良反应,探讨局部晚期鼻咽癌诱导化疗的新方案。方法:2005年11月1日至2008年12月1日,58例局部晚期鼻咽癌患者按照相同的临床分期和性别,随机抽签进入试验组和对照组。试验组29例患者采用多西紫杉醇联合卡铂诱导化疗2个疗程后,行2疗程卡铂单药同期放化疗;对照组29例患者采用5-FU代替多西紫杉醇诱导化疗,余治疗方案同试验组。χ2检验比较两组患者诱导化疗及同期放化疗的近期疗效和不良反应。结果:试验组的平均化疗周期数比对照组多(3.31vs.2.83,P=0.043)。两组近期疗效及1年总生存率差异均无统计学意义(P>0.05)。试验组和对照组Ⅲ度及Ⅲ度以上中性粒细胞减少的发生率分别为72.4%和37.9%,差异有统计学意义(P=0.05)。试验组血小板减少和呕吐发生率均较对照组少,差异有统计学意义(P=0.013)。结论:TC方案治疗局部晚期鼻咽癌的近期疗效与FC方案相似,不良反应可耐受,远期疗效与毒性尚需进一步研究。 Background and Objective. The platinum-based chemotherapy combined with 5-fluorouracil (5-FU) is most frequently used for nasopharyngeal carcinoma (NPC), but the efficacy has been maintained at 50%-60%. Docetaxel is an effective drug for head and neck tumors, its administration is simple, and the administration time is short. This study was to compare the short-term efficacy and toxicity between TC regimen (inductive chemotherapy with docetaxol plus carboplatin) and FC regimen (5-FU plus carboplatin) in local advanced NPC so as to provide a new chemotherapeutic regimen for NPC. Methods: Fifty-eight local advanced NPC patients without previous treatment in Sun Yat-sen University Cancer Center were randomly assigned to receive either TC regimen or FC regimen treatment. The short-term efficacy and adverse events were observed.Results: More chemotherapy cycles were finished in TC group than in FC group (3.31 vs. 2.83, P = 0.043). There was no significant difference in short-term efficacy and 1-year survival rate between the two groups (P 〉 0.05). More Grades 3-4 neutropenia appeared in TC group than in FC group (72.4% vs. 37.9%,P〈 0.05), whereas less thrombocytopenia and emesis occurred in TC than in FC group (P= 0.013 and 0.018, respectively). Conclusions. The short-term efficacy of TC regimen in local advanced NPC is similar to that of FC regimen with tolerable adverse events. But the longterm outcomes and toxicities need to be further investigated.
出处 《癌症》 SCIE CAS CSCD 北大核心 2010年第2期148-152,共5页 Chinese Journal of Cancer
基金 广东省卫生厅基金(B200606s)~~
关键词 鼻咽肿瘤 多西紫杉醇 疗效 不良反应 Nasopharyngeal neoplasm, docetaxel, efficacy, adverse events
  • 相关文献

参考文献18

  • 1AI-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase Ⅲ randomized Intergroup study 0099 [J]. J Clin Oncol, 1998,16(4) : 1310-1317.
  • 2Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study [J]. J Clin Oncol, 2004,22(13):2643-2653.
  • 3Ogawa T, Terada A, Hyodo I, et al. A Phase Ⅰ study of docetaxel and cisplatin for advanced squamous cell carcinoma of the head and neck [J]. Gan To Kagaku Ryoho, 2005,32 (7) :977-981.
  • 4Chan AT, Ma BB, Lo YM, et al. Phase Ⅱ study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA [J]. J Clin Oncol, 2004,22 (15) : 3053-3060.
  • 5Baujat B, Bourhis J, Chan AT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients [J]. Int J Radiat Oncol Biol Phys, 2006,64:47-56.
  • 6Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature [J]. J Clin Oncol, 2004,22(22):4604-4612.
  • 7Nabell L, Spencer S. Docetaxel with concurent radiotherapy in head and neck cancer [J]. Semin Oncol, 2003,30(6 Suppl 18):89-93.
  • 8Hehr T, Classen J, Belka C, et al. Radiation alternating with docetaxel and cisplatin in inoperable recurence of head and neck cancer: a prospective phase Ⅰ/Ⅱ trial [J]. Int J Radiat Oncol Biol Phys, 2005,61 (5) : 1423-1431.
  • 9Hui EP, Ma BB, Leung SF, et al. Randomized phase Ⅱ trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma [J]. J Clin Oncol, 2009,27(2):242-249.
  • 10Douple EB, Richmond RC, O'Hara JA, et al. Carboplatin as a potentiator of radiation therapy [J]. Cancer Treat Rev, 1985,12(Suppl A) : 111-124.

同被引文献91

引证文献14

二级引证文献134

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部